Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Medtronic
Baxter
Boehringer Ingelheim
AstraZeneca

Last Updated: June 4, 2023

NURTEC ODT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Nurtec Odt, and what generic alternatives are available?

Nurtec Odt is a drug marketed by Biohaven Ireland and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and three patent family members in thirty-five countries.

The generic ingredient in NURTEC ODT is rimegepant sulfate. One supplier is listed for this compound. Additional details are available on the rimegepant sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Nurtec Odt

Nurtec Odt will be eligible for patent challenges on February 27, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for NURTEC ODT
International Patents:103
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 2
Clinical Trials: 2
Patent Applications: 1
Drug Prices: Drug price information for NURTEC ODT
What excipients (inactive ingredients) are in NURTEC ODT?NURTEC ODT excipients list
DailyMed Link:NURTEC ODT at DailyMed
Drug patent expirations by year for NURTEC ODT
Drug Prices for NURTEC ODT

See drug prices for NURTEC ODT

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NURTEC ODT
Generic Entry Date for NURTEC ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NURTEC ODT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Antonios LikourezosPhase 4
Weill Medical College of Cornell UniversityPhase 2
Biohaven Pharmaceuticals, Inc.Phase 2

See all NURTEC ODT clinical trials

US Patents and Regulatory Information for NURTEC ODT

NURTEC ODT is protected by five US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NURTEC ODT is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NURTEC ODT

Rimegepant for CGRP related disorders
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Rimegepant for CGRP related disorders
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS

CGRP receptor antagonists
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

CGRP receptor antagonists
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS

N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting NURTEC ODT

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NURTEC ODT

When does loss-of-exclusivity occur for NURTEC ODT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13226361
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2014021032
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 65585
Estimated Expiration: ⤷  Try a Trial

China

Patent: 4136437
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0171620
Estimated Expiration: ⤷  Try a Trial

Patent: 0191655
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 19448
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 20016
Estimated Expiration: ⤷  Try a Trial

Patent: 54681
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 5358
Estimated Expiration: ⤷  Try a Trial

Patent: 1491585
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 20016
Estimated Expiration: ⤷  Try a Trial

Patent: 54681
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 48111
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 34936
Estimated Expiration: ⤷  Try a Trial

Patent: 47050
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 4272
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 08154
Estimated Expiration: ⤷  Try a Trial

Patent: 76253
Estimated Expiration: ⤷  Try a Trial

Patent: 15511581
Estimated Expiration: ⤷  Try a Trial

Patent: 17226693
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 20016
Estimated Expiration: ⤷  Try a Trial

Patent: 54681
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 2171
Estimated Expiration: ⤷  Try a Trial

Patent: 14009544
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 35439
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 20016
Estimated Expiration: ⤷  Try a Trial

Patent: 54681
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 20016
Estimated Expiration: ⤷  Try a Trial

Patent: 54681
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 556
Estimated Expiration: ⤷  Try a Trial

Patent: 295
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 201404834X
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 20016
Estimated Expiration: ⤷  Try a Trial

Patent: 54681
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 2076118
Estimated Expiration: ⤷  Try a Trial

Patent: 2220969
Estimated Expiration: ⤷  Try a Trial

Patent: 140130140
Estimated Expiration: ⤷  Try a Trial

Patent: 200016993
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 42737
Estimated Expiration: ⤷  Try a Trial

Patent: 46031
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NURTEC ODT around the world.

Country Patent Number Title Estimated Expiration
Hungary S2200033 ⤷  Try a Trial
Serbia 53149 ANTAGONISTI RECEPTORA ZA CGRP (CGRP RECEPTOR ANTAGONISTS) ⤷  Try a Trial
Japan 6208154 ⤷  Try a Trial
Slovenia 2488512 ⤷  Try a Trial
South Korea 20120087940 CGRP RECEPTOR ANTAGONISTS ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NURTEC ODT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2488512 2022C/540 Belgium ⤷  Try a Trial PRODUCT NAME: RIMEGEPANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1645 20220426
2488512 PA2022516 Lithuania ⤷  Try a Trial PRODUCT NAME: RIMEGEPANTAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/22/1645 20220425
2488512 LUC00272 Luxembourg ⤷  Try a Trial PRODUCT NAME: RIMEGEPANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/22/1645 20220426
2488512 301187 Netherlands ⤷  Try a Trial PRODUCT NAME: RIMEGEPANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/22/1645 20220426
2488512 33/2022 Austria ⤷  Try a Trial PRODUCT NAME: RIMEGEPANT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1645 (MITTEILUNG) 20220426
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.